Auspex to Present at the J.P. Morgan Healthcare Conference
GLOBE NEWSWIRE via COMTEX
LA JOLLA, Calif., Jan 05, 2015

Auspex Pharmaceuticals, Inc. ASPX, +6.57% a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that Pratik Shah, Ph.D., President and Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 11:30 a.m. PST at the Westin St. Francis in San Francisco.

A live webcast of the presentation will be available through the investor relations section of Auspex Pharmaceuticals' website, www.auspexpharma.com

About Auspex Pharmaceuticals
Auspex Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for hyperkinetic movement disorders and other rare diseases. Auspex employs its proprietary technology to create patent-protected, new chemical entities from known, clinically proven pharmacologics. The company's lead product SD-809 is in final stages of development for the treatment of chorea associated with Huntington's disease, a neurodegenerative movement disorder that impacts cognition, behavior and movements. In addition, Auspex is investing in the broad potential of SD-809 for the treatment of other movement disorders, including tardive dyskinesia and tics associated with Tourette syndrome. The company's pipeline also includes SD-560, being developed for fibrotic conditions. For further information, please visit the company's website www.auspexpharma.com.